Results 81 to 90 of about 655,557 (182)

Cross fire: BTK inhibitor alone or in combination are the best frontline therapy for CLL

open access: yes, 2022
BTK (Bruton's tyrosine kinase) inhibitors are highly effective front-line therapy for CLL (chronic lymphocytic leukemia) due to high response rates and prolonged progression-free survival, even in patients with high-risk disease features.
Theo Sottero   +2 more
core   +1 more source

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao   +4 more
wiley   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

open access: yesThe FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin   +2 more
wiley   +1 more source

Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders

open access: yesPharmacological Research
The Bruton nonreceptor protein-tyrosine kinase (BTK) plays a central role in B cell antigen receptor signaling. Following B cell receptor activation, the Src protein kinase Lyn and the spleen protein kinase (Syk) activate BTK.
Robert Roskoski, Jr
doaj   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

open access: yes
British Journal of Haematology, EarlyView.
Isacco Ferrarini   +19 more
wiley   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran   +2 more
wiley   +1 more source

Management of chronic urticaria: Current status and future prospect

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman   +15 more
wiley   +1 more source

Bruton's Tyrosine Kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages.

open access: yesPLoS Pathogens, 2013
Phagocytosis of the opportunistic fungal pathogen Candida albicans by cells of the innate immune system is vital to prevent infection. Dectin-1 is the major phagocytic receptor involved in anti-fungal immunity. We identify two new interacting proteins of
Karin Strijbis   +11 more
doaj   +1 more source

Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley   +1 more source

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127 [PDF]

open access: yes
Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies.
Brown, Robert J   +52 more
core   +1 more source

Home - About - Disclaimer - Privacy